Altimmune, Inc.

NasdaqGM:ALT 주식 보고서

시가총액: US$506.2m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Altimmune 관리

관리 기준 확인 2/4

Altimmune's CEO는 Vipin Garg, Nov2018 에 임명되었습니다 의 임기는 5.58 년입니다. 총 연간 보상은 $ 5.48M, 11.3% 로 구성됩니다. 11.3% 급여 및 88.7% 보너스(회사 주식 및 옵션 포함). 는 $ 1.73M 가치에 해당하는 회사 주식의 0.41% 직접 소유합니다. 1.73M. 경영진과 이사회의 평균 재임 기간은 각각 3.7 년과 5.7 년입니다.

주요 정보

Vipin Garg

최고 경영자

US$5.5m

총 보상

CEO 급여 비율11.3%
CEO 임기5.6yrs
CEO 소유권0.4%
경영진 평균 재임 기간3.7yrs
이사회 평균 재임 기간5.7yrs

최근 관리 업데이트

Recent updates

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Jun 24

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

May 27

Buy Altimmune's Potential Market Disruption With Pemvidutide

Apr 12

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Mar 27

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Feb 27

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Feb 12

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Feb 10
Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Thoroughly Derisked, Altimmune Is Now A Great Buy

Jan 10

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

Oct 11
Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Jun 27
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

Feb 12
Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Oct 27
We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth

Altimmune: Overreaction On NASH Data Creates Buying Opportunity

Sep 15

Reassessing Altimmune

Sep 07

Altimmune sets new 52-week high on rising volume

Aug 31

Altimmune Q2 2022 Earnings Preview

Aug 10

Altimmune: Several Catalysts In 2 Large Market Indications This Year

Jun 29

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Jun 27
Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Altimmune's New Avatar As A Liver Disease Player

Apr 07

Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Feb 01
Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation

Altimmune: Changing Focus To Pemvidutide In 2022

Jan 03

Altimmune: Changing The Thesis

Oct 16

Here's Why Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Is The Least Of Shareholders Concerns

Sep 17
Here's Why Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Is The Least Of Shareholders Concerns

We're Hopeful That Altimmune (NASDAQ:ALT) Will Use Its Cash Wisely

Aug 06
We're Hopeful That Altimmune (NASDAQ:ALT) Will Use Its Cash Wisely

Altimmune: NASH And Obesity At The End Of The COVID Tunnel

Jul 27

Altimmune rises 5% on positive ALT-801 data in early-stage trial of overweight volunteers

Jun 16

CEO 보상 분석

Vipin Garg 의 보수는 Altimmune 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$93m

Dec 31 2023US$5mUS$620k

-US$88m

Sep 30 2023n/an/a

-US$78m

Jun 30 2023n/an/a

-US$81m

Mar 31 2023n/an/a

-US$85m

Dec 31 2022US$3mUS$580k

-US$85m

Sep 30 2022n/an/a

-US$87m

Jun 30 2022n/an/a

-US$97m

Mar 31 2022n/an/a

-US$102m

Dec 31 2021US$3mUS$566k

-US$97m

Sep 30 2021n/an/a

-US$84m

Jun 30 2021n/an/a

-US$68m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$1mUS$514k

-US$49m

Sep 30 2020n/an/a

-US$43m

Jun 30 2020n/an/a

-US$36m

Mar 31 2020n/an/a

-US$22m

Dec 31 2019US$815kUS$500k

-US$21m

Sep 30 2019n/an/a

-US$42m

Jun 30 2019n/an/a

-US$34m

Mar 31 2019n/an/a

-US$40m

Dec 31 2018US$2mUS$44k

-US$42m

보상 대 시장: Vipin 의 총 보상 ($USD 5.48M )은 US 시장( $USD 2.46M ).

보상과 수익: 회사가 수익성이 없는 동안 Vipin 의 보상이 증가했습니다.

CEO

Vipin Garg (66 yo)

5.6yrs

테뉴어

US$5,482,089

보상

Dr. Vipin K. Garg, Ph D., has been the President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg joined Altimmune in November 2018 with over three decades of expe...

리더십 팀

이름위치테뉴어보상소유권
Vipin Garg
President5.6yrsUS$5.48m0.41%
$ 2.1m
Matthew Harris
Chief Medical Officer4.9yrsUS$2.24m0.076%
$ 382.9k
Raymond Jordt
Chief Business Officer1.4yrsUS$2.94m0.019%
$ 98.1k
Richard Eisenstadt
Chief Financial Officer2.5yrsUS$619.69k0.063%
$ 321.4k
Bertrand Georges
Chief Technology Officer7.1yrs데이터 없음데이터 없음
M. Roberts
Chief Scientific Officer11.5yrsUS$1.41m0.060%
$ 304.7k
Tony Blandin
Vice President of Quality & Compliance Management2.3yrs데이터 없음데이터 없음
Andrew Shutterly
Corporate Controller1.3yrs데이터 없음데이터 없음

3.7yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 관리: ALT 의 관리팀은 경험 ( 3.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Vipin Garg
President5.6yrsUS$5.48m0.41%
$ 2.1m
Mitchel Sayare
Independent Chairman14.2yrsUS$119.68k0.037%
$ 188.2k
John Gill
Independent Director19.8yrsUS$103.68k0.0039%
$ 19.8k
David Drutz
Independent Director7.1yrsUS$109.68k0.042%
$ 212.7k
Philip Hodges
Independent Director7.1yrsUS$115.68k0.037%
$ 189.8k
Klaus Schafer
Independent Director7.1yrsUS$104.68k0.013%
$ 65.6k
Wayne Pisano
Independent Director5.8yrsUS$108.68k0.012%
$ 60.7k
Diane Jorkasky
Independent Director4.1yrsUS$95.68k0%
$ 0
Rohit Loomba
Member of Mash Scientific Advisory Board1.9yrs데이터 없음데이터 없음
Michael Charlton
Member of Mash Scientific Advisory Board1.9yrs데이터 없음데이터 없음
Mazen Noureddin
Member of Mash Scientific Advisory Board1.9yrs데이터 없음데이터 없음
Naga Chalasani
Member of Mash Scientific Advisory Board1.9yrs데이터 없음데이터 없음

5.7yrs

평균 재임 기간

72yo

평균 연령

경험이 풍부한 이사회: ALT 의 이사회는 경험(평균 재직 기간 5.7 년)으로 간주됩니다.